Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DHFR | P00374 | 1/20 | 0.61 |
| ▸ | TK2 | O00142 | 4/20 | 0.48 |
| ▸ | TK1 | P04183 | 4/20 | 0.46 |
| ▸ | BCHE | P06276 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21178588 | 0.90 | DHFR (0.48) | DHFRTK2TK1 | |
| SCHEMBL21179129 | 0.90 | DHFR (0.48) | DHFRTK2TK1 | |
| SCHEMBL22801261 | 0.90 | DHFR (0.48) | DHFRTK2TK1 | |
| SCHEMBL22801208 | 0.90 | DHFR (0.48) | DHFRTK2TK1 | |
| SCHEMBL21178036 | 0.89 | DHFR (0.48) | DHFRTK2TK1 | |
| SCHEMBL24625602 | 0.83 | DHFR (0.41) | DHFRTK2TK1BCHE | |
| SCHEMBL20180458 | 0.82 | DHFR (0.58) | DHFRTK2TK1BCHE | |
| SCHEMBL20180392 | 0.82 | DHFR (0.58) | DHFRTK2TK1BCHE | |
| SCHEMBL23621017 | 0.82 | DHFR (0.58) | DHFRTK2TK1BCHE | |
| SCHEMBL20180532 | 0.82 | DHFR (0.58) | DHFRTK2TK1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220220145-A1 | CYCLIC PHOSPHATE COMPOUNDS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-07-14 | — | — | US | disclosed |
| US-20220220145-A1 | CYCLIC PHOSPHATE COMPOUNDS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-07-14 | — | — | US | disclosed |
| EP-3966221-A1 | CYCLIC PHOSPHATE COMPOUNDS | Ligand Pharmaceuticals Incorporated (US) | 2022-03-16 | — | — | EP | disclosed |
| CN-113939526-A | Cyclic phosphate ester compound | 配体药物公司 | 2022-01-14 | — | — | CN | disclosed |
| WO-2020219464-A1 | CYCLIC PHOSPHATE COMPOUNDS | LIGAND PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
| WO-2020219464-A1 | CYCLIC PHOSPHATE COMPOUNDS | LIGAND PHARMACEUTICALS, INC. (US) | 2020-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220145-A1 | CYCLIC PHOSPHATE COMPOUNDS | PYGL, ALPP, PHPT1 | DHFR 3080/4885TK2 177/4885TK1 338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.